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Alzheimer’s disease (AD) is an irreversible, progressive neurodegenerative disorder 
that is commonly found in the elderly population. AD is characterized pathologically 
by the deposition of amyloid plaques and neurofibrillary tangles in the brain. The 
major component of amyloid plaque is the -amyloid protein (A), a 40-42 amino-
acid residue polypeptide that is generated from the -amyloid precursor protein (APP) 
by the -site APP cleaving enzyme-1 (BACE1) and -secretase. APP can also be 
cleaved by -secretase within the A sequence to form sAPP and C83, which thus 
precludes formation of A.  
 
Advances in AD research over the past three decades have not yet led to effective 
treatments to prevent or cure AD. Therefore, an effective drug for the treatment of AD 
is required. As oligomeric forms of A are thought to be the major toxic species 
which cause AD, therapeutic approaches are now targeting the production, clearance 
or neurotoxicity of A.   
 
It has been reported that glycosaminoglycans (GAGs) such as heparin can influence 
A production by disrupting APP proteolytic processing. Studies have reported that 
heparan sulfate and heparin can directly inhibit BACE1 activity in vitro and thereby 
decrease A production in cell culture. Studies have also shown that heparin binds 
close to the prodomain of the BACE1 zymogen (proBACE1) and that this binding 
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stimulates proBACE1 activity. However, heparin can also inhibit mature BACE1 
activity by binding close to the active site domain of the mature protein. In contrast, 
other groups have reported that heparin stimulates -secretase cleavage of APP in a 
cultured cell line. 
 
As there are conflicting reports on the effect of GAGs on APP processing and A 
production, the effects of heparin or enoxaparin on APP processing was first 
examined in primary cortical cells obtained from transgenic mice expressing human 
APP695 with the Swedish familial AD mutant (Tg2576 mouse). The results showed 
that heparin or enoxaparin (ENO) treatment can lower A secretion from cortical cells 
by decreasing BACE1 and thereby inhibiting -secretase processing of APP. 
Additionally, treatment with heparin or enoxaparin decreased the -secretase 
ADAM10 and inhibited -secretase processing of APP.  
 
The development of GAG analogues which can be used for the treatment of AD will 
require the identification of highly potent and specific compounds that have the ability 
to cross the blood-brain barrier (BBB). Therefore, an aim of the studies in this thesis 
was to examine the structure specificity (molecular size and sulfation degree) of 
GAGs with the aim of identifying more potent and specific GAG-based compounds to 
inhibit APP processing and A production. The effects of various GAGs and sulfated 
polysaccharides on APP processing were tested in primary cortical cells derived from 
Tg2576 mice. The results showed that the effect of GAGs on APP processing was 
both size- and sulfation-dependent. Mucosal heparins (MHs) with small sizes (5 kDa 
and 3kDa) were less potent in reducing A than high molecular weight MHs (6 kDa 
and 12.5 kDa). 6-O-Sulfation was important for the effect on APP processing as 
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heparin lacking 6-O sulfate were less potent than native heparin. However, deletion of 
carboxyl groups on MH had no significant effect on APP processing. These data 
suggest that it might be possible to alter the structure of GAGs to achieve more potent 
and specific inhibitors of APP processing that can cross the blood-brain barrier. 
 
It has been reported that peripheral administration of ENO can reduce the level of A 
and the amyloid plaque load in the brain of APP transgenic mice. However, the exact 
mechanism of these effects has been unclear. Therefore, an aim of this study was to 
examine whether the reduced amyloid plaque load reported to occur in the brains of 
the APP transgenic mice treated with ENO was due to decreased APP processing to 
A caused by ENO treatment. ENO was peripherally injected to Tg2576 mice, and 
the APP processing products and amyloid load in the brains of the mice were 
examined. The study found that ENO treatment decreased the A40/A42 ratio in 
cortex and increased the amyloid plaque load in both cortex and hippocampus, while 
overall APP processing was not significantly influenced by ENO. The exact 
mechanism of these effects remains unknown. These results suggest that the strategy 
of using ENO for the treatment of AD may need further assessment. 
 
As GAGs such as HS are widely expressed in the brain in the form of proteoglycans, 
it is possible that the endogenous HS may also affect APP processing. Therefore, an 
aim of the study was to examine the role of endogenous HS on APP processing and 
A production. To examine this, primary cortical cells derived from Tg2576 mice 
were incubated with a drug or enzyme designed to degrade HS chains from 
endogenous proteoglycans. The results showed that deletion of endogenous HS can 
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reduce the level of BACE1 and ADAM10 and thus inhibit APP processing through - 
and -secretase cleavage pathways similar to exogenous treatment of heparin. These 
findings suggest that regulation of endogenous HS to inhibit APP processing to A 
could be a novel approach for the treatment of AD. 
 
Based on these results, modification of structures of GAGs or sulfate polysaccharides 
may achieve highly potent and specific BBB-permeable compounds which can inhibit 
APP processing to A. Moreover, regulation of endogenous HS can also affect APP 
processing and A production. Therefore, the studies reported in this thesis support 
the view that GAG-based compounds can regulate the A production and strategies 
based on administration of GAGs or the alteration of endogenous GAG metabolism 
may have value for the treatment of AD. 
 
 
 
 
 
 
 
 
